The discovery of the PGT antibody panel (Walker et al., 2011) showed that human donors can produce antibodies roughly tenfold more potent than all previously known broadly neutralizing antibodies (bNAbs) against HIV-1, most of them targeting glycan-dependent epitopes on the envelope glycoprotein, and computed that combinations of such antibodies could cover most of global HIV-1 diversity at vaccine-achievable concentrations — provided a vaccine could elicit them. The source paper's listed limitations split into distinct threads: epitope structures, the elicitation question, in-vivo protective coverage of antibody combinations, in-vitro-to-in-vivo protection ratios, and B-cell screening and serum-breadth completeness. Later work has resolved the first, fourth, and fifth of these and substantially addressed the third (high-resolution PGT epitope structures 2011-2014; the AMP trials and PT80 biomarker validating neutralization-titer-based protection in humans; single-cell and high-throughput repertoire sequencing superseding the 2011 B-cell screen; passive-transfer and passive-administration protection studies). The open problem is elicitation: no immunogen or vaccination regimen has reproducibly elicited a PGT-like glycan-dependent broadly neutralizing antibody response in uninfected humans at protective titers. Germline targeting has primed VRC01-class precursors in humans and, in 2026, elicited full BG18-class (N332-supersite) bNAbs in outbred macaques with up to 67% breadth, narrowing the open problem to reproducible human elicitation at potency, breadth, and serum titers meeting the source paper's protective-coverage logic.

Background

The envelope glycoprotein (Env) of HIV-1 is a trimer of three gp120-gp41 heterodimers and is among the most heavily glycosylated proteins known: roughly half of its exposed surface is covered by host-derived N-linked glycans (sugars attached at asparagine positions, denoted by the residue number, e.g. N332 or N160). Because these glycans are synthesized by the host, they were long viewed as a self-like shield hiding the conserved protein surfaces from antibodies. Broadly neutralizing antibodies (bNAbs) are monoclonal antibodies that neutralize a large fraction of circulating virus isolates rather than a single strain; neutralization is quantified by the IC50IC_{50}, the antibody concentration inhibiting 50% of infection in a standardized single-round pseudovirus assay (TZM-bl reporter cells infected with virus particles engineered to carry one chosen Env and to replicate only once). Virus isolates used to benchmark neutralization are graded on a tier scale of neutralization resistance: tier-2 viruses, derived from primary circulating isolates, are relatively resistant to neutralization and are the standard yardstick for bNAb activity, whereas tier-1 pseudoviruses are neutralized readily, even by non-broadly neutralizing antibodies.

Walker et al. (2011) cultured memory B cells from four HIV-infected donors with exceptionally broad and potent sera at near-clonal density, screened the culture supernatants for neutralization, and recovered 17 new bNAbs (the PGT series) — several about tenfold more potent than the then best bNAbs (PG9, PG16, VRC01). Epitope mapping showed that most recognize glycan-dependent sites: the high-mannose patch — a cluster of unusually mannose-rich N-linked glycans — centered on the N332 and N301 glycans at the base of the V3 loop, the third variable region of gp120 (later called the N332 supersite; PGT121-123, 125-128, 130-131), quaternary epitopes at the trimer apex around N160 that only exist on the assembled trimer (PGT141-145), and a cleavage-dependent gp120-gp41 interface site (PGT151/152).

The paper's forward-looking analysis computed combinatorial coverage: a virus was counted as covered if at least one antibody in a combination had an IC50IC_{50} below a chosen concentration. Adopting protective ratios of 1:100 and 1:500 (required serum concentration relative to in-vitro IC50IC_{50}) from macaque passive-transfer studies, a combination of the potent, non-overlapping antibodies PGT128 and PGT145 would protect against 70% and 40% of a 162-virus cross-clade panel respectively, and the full bNAb arsenal then available against 89% and 62%. The authors concluded that an effective HIV vaccine will likely require the elicitation of a combination of complementary potent neutralizing antibodies, with the PGT antibodies as templates.

How to make a vaccine elicit such antibodies was, and remains, the hard part. PGT-class bNAbs arise during years of infection through affinity maturation — progressive mutation (somatic hypermutation) and selection of B cells in germinal centers — and they typically carry high somatic mutation loads and unusual features such as very long heavy-chain complementarity determining region 3 (HCDR3) loops; their naive precursor B cells are rare in the uninfected repertoire. The dominant strategy is germline targeting: engineer immunogens that bind the unmutated, germline-encoded B-cell receptors of the desired precursor specificity to prime those cells, then deliver sequential boosts designed to guide affinity maturation toward the bNAb state. A quantitative target now exists: the Antibody Mediated Prevention (AMP) trials established the serum neutralization titer (PT80, the predicted dilution of a person's serum giving 80% inhibition against a given virus) as a biomarker of protection, with PT80 around 200 estimated to confer 90% prevention efficacy against a virus population (Gilbert et al., 2022).

As of 2026, human germline-targeting trials have primed precursors of the VRC01 class (CD4-binding-site, not glycan-dependent) at high frequency (Leggat et al., 2022; Caniels et al., 2025), while a protein germline-targeting regimen has elicited complete bNAbs of the BG18 class — an N332-supersite, HCDR3-dominant specificity in the same glycan-dependent family as the PGT antibodies — in outbred macaques, with up to 67% neutralization breadth and protective-tier serum titers in one animal (Steichen et al., 2026). No vaccine has yet elicited a PGT-like glycan-dependent bNAb response in humans.

Problem Statement

This problem is the open core of the limitations listed by Walker et al. (2011) after their discovery of the PGT broadly neutralizing antibody panel; the other limitations they listed (epitope structures, protection-ratio calibration, combinatorial coverage validation, B-cell screening completeness) are resolved or substantially addressed by later work. The open problem, which is the paper's own stated vaccine objective — 'the elicitation of a combination of complementary potent neutralizing antibodies, with the PGT antibodies as templates' — is:

Design an immunogen (or sequence of immunogens) and a vaccination regimen that reproducibly elicits, in uninfected humans, a combination of complementary antibodies of the PGT-like glycan-dependent specificities that the PGT panel defined — drawn from any of the following specificity classes: the high-mannose-patch/N332-supersite class (PGT121-123, 125-128, 130-131; the related BG18 class), the N160-dependent trimer-apex quaternary class (PGT141-145), and the gp120-gp41 interface class (PGT151/152) — at the potency, breadth, and serum titers that the source paper's protective-coverage logic requires.

The three criteria are jointly necessary for one overarching objective — a vaccine-induced, protective combination of PGT-class antibodies in humans: (1) the elicited response — measured in vaccine-elicited serum or in monoclonal antibodies isolated from vaccinees — neutralizes a cross-clade tier-2 pseudovirus panel — chosen independently of the elicited antibodies and comparable in clade diversity to the source paper's 162-virus cross-clade panel — with breadth and potency approaching the PGT reference set: for example, elicited monoclonal antibodies with IC50IC_{50} below roughly 0.1 µg/ml (the source paper's 1:100-rule threshold at an assumed 10 µg/ml elicited serum) that jointly cover the panel at a level approaching the source paper's combinatorial computation (PGT128 plus PGT145 covered 70% and 40% of the 162-virus panel at the 1:100 and 1:500 protective ratios, corresponding to IC50IC_{50} thresholds of roughly 0.1 µg/ml and 0.02 µg/ml at an assumed 10 µg/ml elicited serum; the full bNAb arsenal then available covered 89% and 62%), or serum neutralization titers matching the prevention goal Gilbert et al. (2022) derive from the AMP trials — sustained PT80 above roughly 200, the titer estimated to confer 90% prevention efficacy, against at least 90% of an independently chosen representative circulating-virus panel; (2) the elicited antibodies are genuinely of the PGT-like class, established by dependence on the defining glycans or quaternary contacts — loss of neutralization upon N332K/N301A (or N160K for the apex class) substitution, mutations that remove the N-linked glycan at those positions, trimer-preferring binding, and epitope mapping or structural confirmation; and (3) the response is reproducible, occurring in a substantial fraction of recipients rather than as a single idiosyncratic event.

A demonstrated, mechanistically grounded impossibility — for example, that the human naive B-cell repertoire or affinity-maturation process cannot support these glycan-dependent specificities at protective titers — would answer the question negatively. Empirical progress short of that goal, such as precursor priming in humans or full bNAb elicitation in macaques (achieved for the BG18 class in 2026), sharpens the question but is not by itself an answer, because the open problem is a vaccine that achieves human elicitation, at protective titers, reproducibly.

References

  1. Walker LM, Huber M, Doores KJ, et al. (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-470. DOI: 10.1038/nature10373. https://doi.org/10.1038/nature10373
  2. Pejchal R, Doores KJ, Walker LM, et al. (2011). A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334(6059):1097-1103. DOI: 10.1126/science.1213256. https://doi.org/10.1126/science.1213256
  3. Julien JP, Sok D, Khayat R, et al. (2013). Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathogens 9(5):e1003342. DOI: 10.1371/journal.ppat.1003342. https://doi.org/10.1371/journal.ppat.1003342
  4. Kong L, Lee JH, Doores KJ, et al. (2013). Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Structural & Molecular Biology 20(7):796-803. DOI: 10.1038/nsmb.2594. https://doi.org/10.1038/nsmb.2594
  5. Garces F, Sok D, Kong L, et al. (2014). Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159(1):69-79. DOI: 10.1016/j.cell.2014.09.009. https://doi.org/10.1016/j.cell.2014.09.009
  6. Falkowska E, Le KM, Ramos A, et al. (2014). Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40(5):657-668. DOI: 10.1016/j.immuni.2014.04.009. https://doi.org/10.1016/j.immuni.2014.04.009
  7. Sanders RW, Derking R, Cupo A, et al. (2013). A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathogens 9(9):e1003618. DOI: 10.1371/journal.ppat.1003618. https://doi.org/10.1371/journal.ppat.1003618
  8. Moldt B, Rakasz EG, Schultz N, et al. (2012). Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proceedings of the National Academy of Sciences USA 109(46):18921-18925. DOI: 10.1073/pnas.1214785109. https://doi.org/10.1073/pnas.1214785109
  9. Caskey M, Klein F, Lorenzi JC, et al. (2015). Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522(7557):487-491. DOI: 10.1038/nature14411. https://doi.org/10.1038/nature14411
  10. Sneller MC, Blazkova J, Justement JS, et al. (2022). Combination anti-HIV antibodies provide sustained virological suppression. Nature 606(7913):375-381. DOI: 10.1038/s41586-022-04797-9. https://doi.org/10.1038/s41586-022-04797-9
  11. Corey L, Gilbert PB, Juraska M, et al. (2021). Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. New England Journal of Medicine 384(11):1003-1014. DOI: 10.1056/NEJMoa2031738. https://doi.org/10.1056/NEJMoa2031738
  12. Gilbert PB, Huang Y, deCamp AC, et al. (2022). Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine 28(9):1924-1932. DOI: 10.1038/s41591-022-01953-6. https://doi.org/10.1038/s41591-022-01953-6
  13. DeKosky BJ, Kojima T, Rodin A, et al. (2015). In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nature Medicine 21(1):86-91. DOI: 10.1038/nm.3743. https://doi.org/10.1038/nm.3743
  14. Moyo T, Kitchin D, Moore PL (2020). Targeting the N332-supersite of the HIV-1 envelope for vaccine design. Expert Opinion on Therapeutic Targets 24(6):499-509. DOI: 10.1080/14728222.2020.1752183. https://doi.org/10.1080/14728222.2020.1752183
  15. Leggat DJ, Cohen KW, Willis JR, et al. (2022). Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378(6623):eadd6502. DOI: 10.1126/science.add6502. https://doi.org/10.1126/science.add6502
  16. Caniels TG, Prabhakaran M, Ozorowski G, et al. (2025). Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science 389(6759):eadv5572. DOI: 10.1126/science.adv5572. https://doi.org/10.1126/science.adv5572
  17. Steichen JM, Phung I, Salcedo E, et al. (2024). Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates. Science 384(6697):eadj8321. DOI: 10.1126/science.adj8321. https://doi.org/10.1126/science.adj8321
  18. Steichen JM, Madden PJ, Flynn CT, et al. (2026). Vaccination elicits HIV broadly neutralizing antibodies in primates. Nature 656(8128):723-733. DOI: 10.1038/s41586-026-10837-5. https://doi.org/10.1038/s41586-026-10837-5
  19. Skelly AN, Gristick HB, Li H, et al. (2026). Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design. Science 392(6804):eaec6396. DOI: 10.1126/science.aec6396. https://doi.org/10.1126/science.aec6396
  20. Relano-Rodriguez I, Du J, Lin ZJ, et al. (2026). Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates. Nature Immunology 27(3):586-599. DOI: 10.1038/s41590-025-02408-z. https://doi.org/10.1038/s41590-025-02408-z
  21. Ma KM, Sutton HJ, Pratap PP, et al. (2025). HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates. Science Immunology 10(110):eadt6660. DOI: 10.1126/sciimmunol.adt6660. https://doi.org/10.1126/sciimmunol.adt6660